Scott Sagel
Concepts (402)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cystic Fibrosis | 97 | 2025 | 1053 | 12.350 |
Why?
| Aminophenols | 19 | 2025 | 144 | 3.760 |
Why?
| Kartagener Syndrome | 24 | 2025 | 30 | 3.640 |
Why?
| Ciliary Motility Disorders | 15 | 2025 | 23 | 3.310 |
Why?
| Quinolones | 17 | 2025 | 126 | 2.930 |
Why?
| Cystic Fibrosis Transmembrane Conductance Regulator | 27 | 2025 | 312 | 2.880 |
Why?
| Sputum | 24 | 2023 | 302 | 2.840 |
Why?
| Lung | 25 | 2024 | 3930 | 1.770 |
Why?
| Inflammation | 16 | 2023 | 2736 | 1.740 |
Why?
| Benzodioxoles | 10 | 2025 | 105 | 1.680 |
Why?
| Respiratory Function Tests | 21 | 2024 | 586 | 1.620 |
Why?
| Respiratory System Agents | 3 | 2022 | 22 | 1.530 |
Why?
| Pseudomonas Infections | 11 | 2025 | 221 | 1.390 |
Why?
| Genetic Testing | 7 | 2021 | 428 | 1.380 |
Why?
| Biomarkers | 25 | 2022 | 3973 | 1.380 |
Why?
| Aminopyridines | 6 | 2022 | 97 | 1.370 |
Why?
| Neonatal Screening | 5 | 2021 | 163 | 1.360 |
Why?
| Cilia | 17 | 2025 | 179 | 1.350 |
Why?
| Lung Diseases | 6 | 2023 | 742 | 1.300 |
Why?
| Mycobacterium avium-intracellulare Infection | 3 | 2021 | 61 | 1.270 |
Why?
| Bronchiectasis | 3 | 2023 | 108 | 1.260 |
Why?
| Anti-Bacterial Agents | 15 | 2024 | 1717 | 1.240 |
Why?
| Chloride Channel Agonists | 11 | 2024 | 77 | 1.190 |
Why?
| Child | 74 | 2025 | 20883 | 1.160 |
Why?
| Azithromycin | 6 | 2024 | 93 | 1.150 |
Why?
| Anti-Inflammatory Agents | 4 | 2020 | 480 | 1.090 |
Why?
| Mutation | 29 | 2022 | 3717 | 1.070 |
Why?
| Forced Expiratory Volume | 16 | 2024 | 510 | 1.060 |
Why?
| Bronchoalveolar Lavage Fluid | 7 | 2019 | 644 | 1.040 |
Why?
| Trypsinogen | 3 | 2021 | 10 | 1.030 |
Why?
| Adolescent | 67 | 2025 | 20393 | 1.020 |
Why?
| Disease Progression | 18 | 2024 | 2635 | 0.880 |
Why?
| Vitamins | 2 | 2018 | 174 | 0.870 |
Why?
| Humans | 130 | 2025 | 129650 | 0.810 |
Why?
| Young Adult | 41 | 2025 | 12426 | 0.790 |
Why?
| Antioxidants | 3 | 2018 | 559 | 0.790 |
Why?
| Female | 88 | 2025 | 68776 | 0.780 |
Why?
| Male | 85 | 2025 | 63681 | 0.770 |
Why?
| Pseudomonas aeruginosa | 11 | 2023 | 347 | 0.770 |
Why?
| Algorithms | 4 | 2021 | 1622 | 0.730 |
Why?
| Ethambutol | 1 | 2021 | 25 | 0.730 |
Why?
| Rifampin | 1 | 2021 | 85 | 0.700 |
Why?
| Breath Tests | 5 | 2022 | 91 | 0.660 |
Why?
| Mycobacterium avium Complex | 3 | 2021 | 88 | 0.630 |
Why?
| Child, Preschool | 30 | 2025 | 10517 | 0.600 |
Why?
| Dyneins | 7 | 2024 | 30 | 0.600 |
Why?
| Longitudinal Studies | 13 | 2024 | 2717 | 0.570 |
Why?
| Dietary Supplements | 3 | 2018 | 534 | 0.560 |
Why?
| Malnutrition | 1 | 2018 | 79 | 0.560 |
Why?
| C-Reactive Protein | 8 | 2022 | 401 | 0.550 |
Why?
| Nontuberculous Mycobacteria | 3 | 2023 | 203 | 0.540 |
Why?
| Leukocyte Elastase | 7 | 2023 | 74 | 0.540 |
Why?
| Hospitalization | 3 | 2025 | 2070 | 0.530 |
Why?
| Prospective Studies | 26 | 2025 | 7133 | 0.530 |
Why?
| Drug Discovery | 1 | 2016 | 131 | 0.490 |
Why?
| Leukocyte L1 Antigen Complex | 5 | 2022 | 29 | 0.480 |
Why?
| Infant | 23 | 2025 | 9024 | 0.480 |
Why?
| Drug Combinations | 7 | 2025 | 330 | 0.470 |
Why?
| Infant, Newborn | 16 | 2025 | 5762 | 0.470 |
Why?
| Mycobacterium Infections, Nontuberculous | 4 | 2023 | 352 | 0.460 |
Why?
| Retrospective Studies | 21 | 2025 | 14518 | 0.450 |
Why?
| Metabolomics | 1 | 2019 | 652 | 0.450 |
Why?
| Adult | 42 | 2025 | 35576 | 0.440 |
Why?
| Nitric Oxide | 5 | 2019 | 902 | 0.440 |
Why?
| Automation | 1 | 2014 | 82 | 0.430 |
Why?
| Granulocyte Colony-Stimulating Factor | 4 | 2022 | 72 | 0.430 |
Why?
| Exocrine Pancreatic Insufficiency | 2 | 2010 | 20 | 0.420 |
Why?
| United States | 20 | 2025 | 13903 | 0.420 |
Why?
| Indoles | 3 | 2025 | 387 | 0.420 |
Why?
| Clinical Trials as Topic | 5 | 2015 | 1004 | 0.410 |
Why?
| Pyrazoles | 3 | 2025 | 405 | 0.410 |
Why?
| Tuberculosis, Pulmonary | 1 | 2014 | 135 | 0.400 |
Why?
| Respiratory System | 4 | 2019 | 154 | 0.390 |
Why?
| Microbiota | 5 | 2023 | 730 | 0.380 |
Why?
| Sweat | 4 | 2020 | 46 | 0.380 |
Why?
| Otorhinolaryngologic Diseases | 1 | 2011 | 15 | 0.370 |
Why?
| Sensitivity and Specificity | 7 | 2021 | 1838 | 0.360 |
Why?
| Cohort Studies | 14 | 2025 | 5420 | 0.360 |
Why?
| Tomography, X-Ray Computed | 6 | 2017 | 2535 | 0.360 |
Why?
| Vitamin K Deficiency | 1 | 2010 | 9 | 0.360 |
Why?
| Vitamin A Deficiency | 1 | 2010 | 26 | 0.350 |
Why?
| Staphylococcal Infections | 3 | 2019 | 393 | 0.350 |
Why?
| Cytokines | 6 | 2023 | 2017 | 0.340 |
Why?
| Quality of Life | 5 | 2024 | 2704 | 0.340 |
Why?
| Severity of Illness Index | 10 | 2024 | 2742 | 0.340 |
Why?
| Otitis Media with Effusion | 2 | 2025 | 21 | 0.330 |
Why?
| Bronchoscopy | 2 | 2008 | 216 | 0.330 |
Why?
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2009 | 6 | 0.320 |
Why?
| Lactoferrin | 1 | 2009 | 28 | 0.310 |
Why?
| Bronchitis | 1 | 2009 | 43 | 0.310 |
Why?
| Muramidase | 1 | 2009 | 77 | 0.310 |
Why?
| Proteomics | 3 | 2022 | 1062 | 0.300 |
Why?
| Vitamin D Deficiency | 1 | 2010 | 176 | 0.300 |
Why?
| Treatment Outcome | 14 | 2025 | 10230 | 0.300 |
Why?
| Tomography | 2 | 2018 | 24 | 0.300 |
Why?
| Diverticulum | 1 | 2007 | 11 | 0.280 |
Why?
| Tracheal Diseases | 1 | 2007 | 16 | 0.280 |
Why?
| Blood Glucose | 4 | 2023 | 2097 | 0.280 |
Why?
| Administration, Oral | 3 | 2018 | 786 | 0.280 |
Why?
| Tracheoesophageal Fistula | 1 | 2007 | 33 | 0.270 |
Why?
| Data Interpretation, Statistical | 2 | 2021 | 335 | 0.270 |
Why?
| Genotype | 10 | 2025 | 1839 | 0.270 |
Why?
| Digestive System Surgical Procedures | 1 | 2007 | 96 | 0.260 |
Why?
| Specimen Handling | 2 | 2020 | 164 | 0.260 |
Why?
| Heterotaxy Syndrome | 2 | 2023 | 10 | 0.260 |
Why?
| Reproductive Health | 2 | 2017 | 86 | 0.260 |
Why?
| Phenotype | 8 | 2025 | 3076 | 0.250 |
Why?
| Proteins | 4 | 2024 | 942 | 0.250 |
Why?
| Respiratory Distress Syndrome, Newborn | 2 | 2025 | 103 | 0.250 |
Why?
| Bacteria | 5 | 2023 | 821 | 0.240 |
Why?
| Leukocyte Count | 5 | 2012 | 326 | 0.240 |
Why?
| Middle Ear Ventilation | 1 | 2025 | 14 | 0.240 |
Why?
| Hearing Loss, Conductive | 1 | 2025 | 25 | 0.240 |
Why?
| Meconium Ileus | 1 | 2024 | 5 | 0.240 |
Why?
| Respiratory Tract Infections | 5 | 2024 | 376 | 0.230 |
Why?
| Interleukin-8 | 7 | 2012 | 262 | 0.230 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2005 | 119 | 0.230 |
Why?
| Age Factors | 5 | 2020 | 3144 | 0.230 |
Why?
| Rhinitis | 2 | 2019 | 152 | 0.220 |
Why?
| Chlorides | 3 | 2022 | 139 | 0.220 |
Why?
| Probability | 3 | 2016 | 306 | 0.220 |
Why?
| Situs Inversus | 1 | 2023 | 3 | 0.220 |
Why?
| DNA, Bacterial | 4 | 2017 | 324 | 0.220 |
Why?
| Oropharynx | 3 | 2015 | 44 | 0.220 |
Why?
| Cytoskeletal Proteins | 4 | 2024 | 146 | 0.220 |
Why?
| Pyridines | 2 | 2024 | 478 | 0.220 |
Why?
| Models, Neurological | 1 | 2006 | 242 | 0.210 |
Why?
| Follow-Up Studies | 7 | 2018 | 4897 | 0.210 |
Why?
| Axonemal Dyneins | 4 | 2025 | 9 | 0.210 |
Why?
| Fetal Diseases | 1 | 2024 | 158 | 0.210 |
Why?
| Sinusitis | 2 | 2019 | 210 | 0.210 |
Why?
| Mucociliary Clearance | 2 | 2021 | 42 | 0.210 |
Why?
| Neuronal Plasticity | 1 | 2006 | 280 | 0.210 |
Why?
| Metagenome | 3 | 2013 | 141 | 0.200 |
Why?
| Monitoring, Immunologic | 1 | 2002 | 23 | 0.200 |
Why?
| Respiration Disorders | 1 | 2023 | 72 | 0.200 |
Why?
| Genetic Markers | 4 | 2016 | 338 | 0.200 |
Why?
| Uteroglobin | 1 | 2022 | 23 | 0.200 |
Why?
| Calreticulin | 1 | 2022 | 27 | 0.200 |
Why?
| HMGB Proteins | 1 | 2022 | 18 | 0.190 |
Why?
| Chemistry, Clinical | 1 | 2002 | 12 | 0.190 |
Why?
| Serum Amyloid A Protein | 2 | 2019 | 31 | 0.190 |
Why?
| Synapses | 1 | 2006 | 400 | 0.190 |
Why?
| Peptide Hydrolases | 1 | 2023 | 107 | 0.190 |
Why?
| Hydrogen | 1 | 2022 | 65 | 0.190 |
Why?
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2021 | 11 | 0.190 |
Why?
| Prognosis | 5 | 2018 | 3794 | 0.190 |
Why?
| Body Mass Index | 5 | 2020 | 2273 | 0.190 |
Why?
| Cross-Sectional Studies | 8 | 2024 | 5066 | 0.180 |
Why?
| Antibiotics, Antitubercular | 1 | 2021 | 37 | 0.180 |
Why?
| Desmosine | 2 | 2012 | 6 | 0.180 |
Why?
| Disease Management | 3 | 2015 | 589 | 0.180 |
Why?
| DNA Mutational Analysis | 5 | 2014 | 387 | 0.180 |
Why?
| Leptin | 1 | 2022 | 219 | 0.180 |
Why?
| Rhodospirillaceae | 1 | 2020 | 4 | 0.170 |
Why?
| Cross-Over Studies | 2 | 2021 | 521 | 0.170 |
Why?
| Glucose | 2 | 2023 | 1003 | 0.170 |
Why?
| Glucose Tolerance Test | 4 | 2023 | 356 | 0.170 |
Why?
| Mycobacterium abscessus | 1 | 2021 | 107 | 0.170 |
Why?
| Patient Acuity | 1 | 2019 | 45 | 0.160 |
Why?
| Insulin-Like Growth Factor I | 1 | 2022 | 307 | 0.160 |
Why?
| Proteome | 2 | 2022 | 443 | 0.160 |
Why?
| Antitubercular Agents | 1 | 2021 | 200 | 0.160 |
Why?
| Sleep Apnea, Central | 1 | 1999 | 10 | 0.160 |
Why?
| Alleles | 4 | 2017 | 845 | 0.160 |
Why?
| Machine Learning | 1 | 2024 | 443 | 0.160 |
Why?
| Autonomic Nervous System Diseases | 1 | 1999 | 34 | 0.160 |
Why?
| Pneumonia | 2 | 2017 | 616 | 0.160 |
Why?
| Predictive Value of Tests | 4 | 2023 | 1952 | 0.150 |
Why?
| Respiratory Tract Diseases | 1 | 2020 | 148 | 0.150 |
Why?
| Image Processing, Computer-Assisted | 2 | 2018 | 744 | 0.150 |
Why?
| Hypoglycemia | 1 | 2023 | 427 | 0.150 |
Why?
| Case-Control Studies | 6 | 2020 | 3381 | 0.150 |
Why?
| Nutritional Status | 2 | 2018 | 328 | 0.150 |
Why?
| Oxidative Stress | 2 | 2018 | 1269 | 0.150 |
Why?
| Diagnostic Techniques and Procedures | 1 | 2018 | 19 | 0.150 |
Why?
| Air | 1 | 2018 | 36 | 0.150 |
Why?
| Lipids | 1 | 2022 | 625 | 0.150 |
Why?
| Saliva | 2 | 2015 | 209 | 0.150 |
Why?
| Aptamers, Nucleotide | 1 | 2019 | 77 | 0.150 |
Why?
| Hirschsprung Disease | 1 | 1999 | 83 | 0.140 |
Why?
| Double-Blind Method | 3 | 2018 | 1876 | 0.140 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2023 | 1198 | 0.140 |
Why?
| Reproductive Health Services | 1 | 2017 | 16 | 0.140 |
Why?
| Neutrophils | 3 | 2015 | 1205 | 0.140 |
Why?
| Respiration | 1 | 2018 | 191 | 0.140 |
Why?
| Health Services Misuse | 1 | 2017 | 35 | 0.140 |
Why?
| Tobramycin | 2 | 2023 | 51 | 0.140 |
Why?
| Clofazimine | 1 | 2017 | 15 | 0.140 |
Why?
| Coinfection | 2 | 2020 | 131 | 0.140 |
Why?
| Neurons | 1 | 2006 | 1511 | 0.130 |
Why?
| Body Height | 1 | 2017 | 193 | 0.130 |
Why?
| Axoneme | 2 | 2013 | 9 | 0.130 |
Why?
| Immunologic Tests | 1 | 2016 | 16 | 0.130 |
Why?
| Sexual Health | 1 | 2017 | 54 | 0.130 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 221 | 0.130 |
Why?
| Postoperative Complications | 1 | 2007 | 2483 | 0.130 |
Why?
| Middle Aged | 15 | 2021 | 31154 | 0.130 |
Why?
| Body Weight | 1 | 2020 | 940 | 0.120 |
Why?
| Dried Blood Spot Testing | 1 | 2016 | 94 | 0.120 |
Why?
| Time Factors | 4 | 2018 | 6556 | 0.120 |
Why?
| Exome | 5 | 2014 | 220 | 0.120 |
Why?
| Spirometry | 4 | 2015 | 257 | 0.120 |
Why?
| Patient Selection | 1 | 2019 | 663 | 0.120 |
Why?
| Diagnostic Tests, Routine | 1 | 2016 | 102 | 0.120 |
Why?
| Targeted Gene Repair | 1 | 2015 | 1 | 0.120 |
Why?
| Prevalence | 2 | 2019 | 2564 | 0.120 |
Why?
| Zebrafish | 3 | 2013 | 458 | 0.120 |
Why?
| Molecular Targeted Therapy | 1 | 2018 | 390 | 0.120 |
Why?
| Pedigree | 5 | 2013 | 487 | 0.120 |
Why?
| Gene Expression Profiling | 3 | 2018 | 1706 | 0.120 |
Why?
| Insulin Resistance | 1 | 2023 | 1165 | 0.120 |
Why?
| Microtubule-Associated Proteins | 2 | 2013 | 192 | 0.120 |
Why?
| Bacteria, Anaerobic | 2 | 2011 | 23 | 0.110 |
Why?
| Hyperglycemia | 1 | 2018 | 328 | 0.110 |
Why?
| Nasal Mucosa | 4 | 2019 | 107 | 0.110 |
Why?
| Microscopy, Electron, Transmission | 4 | 2016 | 146 | 0.110 |
Why?
| Survival Rate | 2 | 2018 | 1877 | 0.110 |
Why?
| Venous Thromboembolism | 1 | 2017 | 284 | 0.110 |
Why?
| Ubiquinone | 2 | 2010 | 28 | 0.110 |
Why?
| Antigens, Surface | 1 | 2013 | 151 | 0.100 |
Why?
| Homozygote | 3 | 2020 | 193 | 0.100 |
Why?
| Pyrrolidines | 2 | 2024 | 67 | 0.100 |
Why?
| Intestine, Small | 1 | 2014 | 150 | 0.100 |
Why?
| Vital Capacity | 1 | 2014 | 291 | 0.100 |
Why?
| Sexual Behavior | 1 | 2017 | 483 | 0.100 |
Why?
| GTP-Binding Proteins | 1 | 2013 | 157 | 0.100 |
Why?
| Neutrophil Activation | 1 | 2013 | 79 | 0.100 |
Why?
| Linear Models | 3 | 2024 | 819 | 0.100 |
Why?
| Mycobacterium Infections | 1 | 2013 | 62 | 0.100 |
Why?
| Precision Medicine | 1 | 2016 | 387 | 0.100 |
Why?
| Elastin | 1 | 2012 | 77 | 0.100 |
Why?
| Models, Statistical | 1 | 2016 | 623 | 0.090 |
Why?
| DNA | 2 | 2018 | 1400 | 0.090 |
Why?
| Proteolysis | 1 | 2012 | 166 | 0.090 |
Why?
| Mycobacterium | 1 | 2013 | 106 | 0.090 |
Why?
| Glycoproteins | 1 | 2013 | 338 | 0.090 |
Why?
| Nasal Cavity | 1 | 2011 | 51 | 0.090 |
Why?
| Turbinates | 1 | 2011 | 16 | 0.090 |
Why?
| Polymerase Chain Reaction | 2 | 2011 | 1038 | 0.090 |
Why?
| Tumor Suppressor Proteins | 1 | 2013 | 317 | 0.090 |
Why?
| Biomarkers, Pharmacological | 1 | 2010 | 26 | 0.090 |
Why?
| Dinoprost | 1 | 2010 | 44 | 0.090 |
Why?
| Inflammation Mediators | 2 | 2005 | 505 | 0.090 |
Why?
| Leukocytes, Mononuclear | 1 | 2013 | 545 | 0.090 |
Why?
| Biopsy | 4 | 2015 | 1097 | 0.090 |
Why?
| Practice Guidelines as Topic | 1 | 2018 | 1501 | 0.090 |
Why?
| Metagenomics | 2 | 2021 | 156 | 0.090 |
Why?
| Interprofessional Relations | 1 | 2012 | 277 | 0.080 |
Why?
| Microbial Sensitivity Tests | 2 | 2021 | 352 | 0.080 |
Why?
| Diabetes Mellitus | 1 | 2018 | 1001 | 0.080 |
Why?
| Canada | 2 | 2024 | 350 | 0.080 |
Why?
| Chronic Disease | 2 | 2015 | 1720 | 0.080 |
Why?
| Morbidity | 2 | 2018 | 302 | 0.080 |
Why?
| Membrane Potentials | 2 | 2010 | 293 | 0.080 |
Why?
| Lung Injury | 1 | 2012 | 210 | 0.080 |
Why?
| Pseudomonas | 2 | 2022 | 28 | 0.080 |
Why?
| Exotoxins | 1 | 2008 | 15 | 0.080 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2023 | 2441 | 0.080 |
Why?
| Confidence Intervals | 1 | 2009 | 317 | 0.080 |
Why?
| Heterozygote | 1 | 2009 | 272 | 0.070 |
Why?
| Administration, Inhalation | 2 | 2023 | 666 | 0.070 |
Why?
| Electric Impedance | 2 | 2018 | 101 | 0.070 |
Why?
| Peroxidase | 2 | 2022 | 174 | 0.070 |
Why?
| Otorhinolaryngologic Surgical Procedures | 1 | 2007 | 38 | 0.070 |
Why?
| Pregnancy | 4 | 2024 | 6402 | 0.070 |
Why?
| Pregnancy Rate | 2 | 2017 | 61 | 0.070 |
Why?
| Evidence-Based Medicine | 1 | 2011 | 718 | 0.070 |
Why?
| RNA Precursors | 1 | 2008 | 147 | 0.070 |
Why?
| Sequence Analysis, DNA | 3 | 2015 | 779 | 0.070 |
Why?
| Genomics | 2 | 2021 | 716 | 0.070 |
Why?
| DNA-Binding Proteins | 1 | 2014 | 1443 | 0.070 |
Why?
| Diagnostic Errors | 1 | 2007 | 162 | 0.060 |
Why?
| Biomedical Research | 1 | 2012 | 638 | 0.060 |
Why?
| Reproducibility of Results | 3 | 2010 | 3083 | 0.060 |
Why?
| Genetic Predisposition to Disease | 2 | 2018 | 2282 | 0.060 |
Why?
| RNA, Messenger | 1 | 2013 | 2708 | 0.060 |
Why?
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2005 | 25 | 0.060 |
Why?
| Tympanic Membrane Perforation | 1 | 2025 | 15 | 0.060 |
Why?
| Audiometry, Pure-Tone | 1 | 2025 | 28 | 0.060 |
Why?
| Needs Assessment | 2 | 2017 | 360 | 0.060 |
Why?
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 14 | 0.060 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 81 | 0.060 |
Why?
| Colorado | 2 | 2018 | 4421 | 0.060 |
Why?
| Cephalosporins | 1 | 2024 | 40 | 0.060 |
Why?
| Staphylococcus aureus | 1 | 2008 | 438 | 0.060 |
Why?
| Reference Values | 2 | 2017 | 793 | 0.060 |
Why?
| Vasodilator Agents | 1 | 2006 | 326 | 0.060 |
Why?
| Exercise Tolerance | 1 | 2006 | 273 | 0.050 |
Why?
| Microscopy, Electron | 2 | 2015 | 426 | 0.050 |
Why?
| Diabetic Retinopathy | 1 | 2006 | 176 | 0.050 |
Why?
| Quinolines | 1 | 2024 | 156 | 0.050 |
Why?
| Piperazines | 1 | 2006 | 342 | 0.050 |
Why?
| Symptom Assessment | 1 | 2024 | 125 | 0.050 |
Why?
| Immunity, Innate | 1 | 2009 | 804 | 0.050 |
Why?
| Cluster Analysis | 1 | 2024 | 482 | 0.050 |
Why?
| Pancreatic Elastase | 1 | 2022 | 60 | 0.050 |
Why?
| Glucagon | 1 | 2023 | 105 | 0.050 |
Why?
| Cell Count | 1 | 2002 | 314 | 0.050 |
Why?
| Aspergillus fumigatus | 1 | 2021 | 23 | 0.050 |
Why?
| Constipation | 1 | 2022 | 88 | 0.050 |
Why?
| Nucleotides | 1 | 2022 | 122 | 0.050 |
Why?
| Computer Simulation | 1 | 2006 | 943 | 0.050 |
Why?
| Down Syndrome | 1 | 2007 | 481 | 0.040 |
Why?
| Cough | 1 | 2001 | 116 | 0.040 |
Why?
| Symptom Flare Up | 1 | 2020 | 38 | 0.040 |
Why?
| Mutant Proteins | 1 | 2020 | 99 | 0.040 |
Why?
| Observational Studies as Topic | 1 | 2021 | 110 | 0.040 |
Why?
| Recovery of Function | 1 | 2024 | 642 | 0.040 |
Why?
| Prediabetic State | 1 | 2023 | 246 | 0.040 |
Why?
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 1279 | 0.040 |
Why?
| Asthma | 2 | 2013 | 2230 | 0.040 |
Why?
| British Columbia | 1 | 2018 | 14 | 0.040 |
Why?
| Fatal Outcome | 1 | 1999 | 300 | 0.040 |
Why?
| Pilot Projects | 2 | 2017 | 1587 | 0.040 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 958 | 0.040 |
Why?
| Blood Glucose Self-Monitoring | 1 | 2023 | 601 | 0.040 |
Why?
| Hospitals | 1 | 2022 | 637 | 0.040 |
Why?
| Early Medical Intervention | 1 | 2018 | 57 | 0.040 |
Why?
| Length of Stay | 1 | 2022 | 1127 | 0.030 |
Why?
| Ultrasonography, Prenatal | 1 | 1999 | 271 | 0.030 |
Why?
| Age Distribution | 1 | 2017 | 372 | 0.030 |
Why?
| Ontario | 1 | 2016 | 90 | 0.030 |
Why?
| Radiography, Thoracic | 1 | 2017 | 168 | 0.030 |
Why?
| Microscopy, Video | 1 | 2015 | 25 | 0.030 |
Why?
| Respiratory Therapy | 1 | 2015 | 23 | 0.030 |
Why?
| Radiography | 1 | 2017 | 798 | 0.030 |
Why?
| Respiratory Syncytial Virus Vaccines | 1 | 2015 | 34 | 0.030 |
Why?
| Regression Analysis | 1 | 2017 | 993 | 0.030 |
Why?
| Surveys and Questionnaires | 2 | 2017 | 5406 | 0.030 |
Why?
| Enterobacteriaceae | 1 | 2015 | 39 | 0.030 |
Why?
| North America | 1 | 2015 | 291 | 0.030 |
Why?
| Staphylococcus | 1 | 2015 | 74 | 0.030 |
Why?
| Enterobacteriaceae Infections | 1 | 2015 | 41 | 0.030 |
Why?
| Risk Factors | 2 | 2019 | 9765 | 0.030 |
Why?
| Hypertension, Pulmonary | 1 | 2006 | 1894 | 0.030 |
Why?
| Pneumococcal Vaccines | 1 | 2015 | 140 | 0.030 |
Why?
| Societies, Medical | 1 | 2018 | 751 | 0.030 |
Why?
| Genetic Therapy | 1 | 2016 | 292 | 0.030 |
Why?
| Sex Factors | 1 | 2020 | 1968 | 0.030 |
Why?
| Counseling | 1 | 2017 | 385 | 0.030 |
Why?
| Genotyping Techniques | 1 | 2014 | 72 | 0.030 |
Why?
| Planarians | 1 | 2013 | 1 | 0.030 |
Why?
| Chlamydomonas | 1 | 2013 | 2 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2017 | 1502 | 0.030 |
Why?
| Xenopus laevis | 1 | 2013 | 99 | 0.030 |
Why?
| Open Reading Frames | 1 | 2013 | 117 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2014 | 544 | 0.030 |
Why?
| Cytoplasm | 1 | 2013 | 263 | 0.030 |
Why?
| Insulin | 1 | 2023 | 2326 | 0.030 |
Why?
| Genes, Recessive | 1 | 2012 | 76 | 0.030 |
Why?
| Computer Communication Networks | 1 | 2012 | 32 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2017 | 2012 | 0.020 |
Why?
| Placebos | 1 | 2012 | 201 | 0.020 |
Why?
| Superoxides | 1 | 2013 | 201 | 0.020 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 331 | 0.020 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2012 | 135 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2013 | 376 | 0.020 |
Why?
| Genetic Association Studies | 1 | 2014 | 360 | 0.020 |
Why?
| Airway Remodeling | 1 | 2012 | 61 | 0.020 |
Why?
| DNA Barcoding, Taxonomic | 1 | 2011 | 18 | 0.020 |
Why?
| Biota | 1 | 2011 | 35 | 0.020 |
Why?
| Logistic Models | 1 | 2016 | 1988 | 0.020 |
Why?
| Protein Isoforms | 1 | 2012 | 391 | 0.020 |
Why?
| Protein Structure, Tertiary | 1 | 2013 | 840 | 0.020 |
Why?
| Incidence | 1 | 2017 | 2644 | 0.020 |
Why?
| Influenza Vaccines | 1 | 2015 | 532 | 0.020 |
Why?
| Autoantigens | 1 | 2013 | 417 | 0.020 |
Why?
| Biofilms | 1 | 2013 | 244 | 0.020 |
Why?
| Ion Channels | 1 | 2010 | 133 | 0.020 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 487 | 0.020 |
Why?
| Cell Cycle Proteins | 1 | 2013 | 586 | 0.020 |
Why?
| Registries | 1 | 2017 | 1896 | 0.020 |
Why?
| Interleukin-6 | 1 | 2012 | 720 | 0.020 |
Why?
| Polymorphism, Genetic | 1 | 2011 | 640 | 0.020 |
Why?
| Genes, rRNA | 1 | 2007 | 41 | 0.020 |
Why?
| Mexico | 1 | 2008 | 190 | 0.020 |
Why?
| gamma-Tocopherol | 1 | 2007 | 8 | 0.020 |
Why?
| beta Carotene | 1 | 2007 | 21 | 0.020 |
Why?
| Genes, Bacterial | 1 | 2007 | 157 | 0.020 |
Why?
| Micelles | 1 | 2007 | 37 | 0.020 |
Why?
| Animals | 3 | 2013 | 35361 | 0.020 |
Why?
| Epithelial Cells | 1 | 2013 | 1065 | 0.020 |
Why?
| Protein Binding | 1 | 2013 | 2121 | 0.020 |
Why?
| Biological Availability | 1 | 2007 | 147 | 0.020 |
Why?
| Leukocytes | 1 | 2008 | 304 | 0.020 |
Why?
| ROC Curve | 1 | 2008 | 503 | 0.020 |
Why?
| Research Design | 1 | 2012 | 1044 | 0.020 |
Why?
| Aged | 2 | 2017 | 22103 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 769 | 0.020 |
Why?
| Sildenafil Citrate | 1 | 2006 | 59 | 0.020 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 985 | 0.020 |
Why?
| Acute Disease | 1 | 2008 | 980 | 0.020 |
Why?
| Aged, 80 and over | 1 | 2017 | 7086 | 0.020 |
Why?
| Sulfones | 1 | 2006 | 108 | 0.020 |
Why?
| Genetic Carrier Screening | 1 | 2004 | 26 | 0.010 |
Why?
| Purines | 1 | 2006 | 172 | 0.010 |
Why?
| Rats | 1 | 2013 | 5500 | 0.010 |
Why?
| Infant Care | 1 | 2004 | 46 | 0.010 |
Why?
| Gene Expression Regulation | 1 | 2013 | 2548 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 2007 | 2832 | 0.010 |
Why?
| Infant Nutritional Physiological Phenomena | 1 | 2004 | 137 | 0.010 |
Why?
|
|
Sagel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|